In Vitro Models of Head and Neck Cancer: From Primitive to Most Advanced.

Irina Arutyunyan, Enar Jumaniyazova, Andrey Makarov, Timur Fatkhudinov
Author Information
  1. Irina Arutyunyan: Research Institute of Molecular and Cellular Medicine, RUDN University, 6 Miklukho-Maklaya Street, 117198 Moscow, Russia. ORCID
  2. Enar Jumaniyazova: Research Institute of Molecular and Cellular Medicine, RUDN University, 6 Miklukho-Maklaya Street, 117198 Moscow, Russia.
  3. Andrey Makarov: Research Institute of Molecular and Cellular Medicine, RUDN University, 6 Miklukho-Maklaya Street, 117198 Moscow, Russia.
  4. Timur Fatkhudinov: Research Institute of Molecular and Cellular Medicine, RUDN University, 6 Miklukho-Maklaya Street, 117198 Moscow, Russia. ORCID

Abstract

For several decades now, researchers have been trying to answer the demand of clinical oncologists to create an ideal preclinical model of head and neck squamous cell carcinoma (HNSCC) that is accessible, reproducible, and relevant. Over the past years, the development of cellular technologies has naturally allowed us to move from primitive short-lived primary 2D cell cultures to complex patient-derived 3D models that reproduce the cellular composition, architecture, mutational, or viral load of native tumor tissue. Depending on the tasks and capabilities, a scientific laboratory can choose from several types of models: primary cell cultures, immortalized cell lines, spheroids or heterospheroids, tissue engineering models, bioprinted models, organoids, tumor explants, and histocultures. HNSCC in vitro models make it possible to screen agents with potential antitumor activity, study the contribution of the tumor microenvironment to its progression and metastasis, determine the prognostic significance of individual biomarkers (including using genetic engineering methods), study the effect of viral infection on the pathogenesis of the disease, and adjust treatment tactics for a specific patient or groups of patients. Promising experimental results have created a scientific basis for the registration of several clinical studies using HNSCC in vitro models.

Keywords

References

  1. Oral Oncol. 2020 Apr;103:104613 [PMID: 32120342]
  2. Arch Med Sci. 2018 Jun;14(4):910-919 [PMID: 30002710]
  3. Small. 2018 Mar;14(13):e1702858 [PMID: 29450963]
  4. J Pers Med. 2022 Nov 21;12(11): [PMID: 36422115]
  5. J Cell Sci. 2007 Dec 15;120(Pt 24):4332-44 [PMID: 18042624]
  6. Cancers (Basel). 2023 Jul 31;15(15): [PMID: 37568710]
  7. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59(1):59-63 [PMID: 1696042]
  8. Biomater Sci. 2020 Jun 7;8(11):3078-3094 [PMID: 32347842]
  9. Cells. 2020 Nov 23;9(11): [PMID: 33238461]
  10. Cell Biosci. 2022 Sep 11;12(1):155 [PMID: 36089610]
  11. Biotechnol J. 2008 Oct;3(9-10):1172-84 [PMID: 18566957]
  12. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1319-27 [PMID: 12128135]
  13. Cancer Res. 2010 May 15;70(10):3925-34 [PMID: 20442295]
  14. Anticancer Res. 2017 May;37(5):2201-2210 [PMID: 28476783]
  15. Oncol Rep. 2016 Apr;35(4):2431-40 [PMID: 26797047]
  16. Curr Med Sci. 2019 Jun;39(3):403-409 [PMID: 31209810]
  17. Int J Mol Sci. 2018 Jan 18;19(1): [PMID: 29346265]
  18. Head Neck. 2007 Feb;29(2):163-88 [PMID: 17312569]
  19. Cancers (Basel). 2022 Jan 08;14(2): [PMID: 35053466]
  20. Ann Biomed Eng. 2012 Jun;40(6):1277-88 [PMID: 21997391]
  21. Cancers (Basel). 2019 Dec 30;12(1): [PMID: 31905951]
  22. Biomedicines. 2023 Jun 20;11(6): [PMID: 37371868]
  23. Cancers (Basel). 2021 Feb 19;13(4): [PMID: 33669619]
  24. Transl Lung Cancer Res. 2020 Oct;9(5):2214-2232 [PMID: 33209645]
  25. Free Radic Res. 2017 Oct;51(9-10):861-871 [PMID: 29076398]
  26. Mater Sci Eng C Mater Biol Appl. 2016 May;62:215-25 [PMID: 26952417]
  27. Biomedicines. 2022 Dec 19;10(12): [PMID: 36552043]
  28. Proteomics. 2010 May;10(9):1886-90 [PMID: 20162561]
  29. Nat Rev Cancer. 2004 Nov;4(11):891-9 [PMID: 15516961]
  30. Bioengineering (Basel). 2020 Nov 07;7(4): [PMID: 33171883]
  31. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3294-8 [PMID: 8475071]
  32. Future Sci OA. 2017 Mar 07;3(2):FSO174 [PMID: 28670466]
  33. J Hematol Oncol. 2020 Jul 16;13(1):97 [PMID: 32677979]
  34. Oral Oncol. 2018 Dec;87:49-57 [PMID: 30527243]
  35. Cell. 2016 Jun 16;165(7):1586-1597 [PMID: 27315476]
  36. Exp Ther Med. 2022 Jun 22;24(2):533 [PMID: 35837055]
  37. Oncotarget. 2016 Jul 19;7(29):45745-45756 [PMID: 27304190]
  38. Int J Pharm. 2022 Apr 5;617:121585 [PMID: 35176332]
  39. ACS Biomater Sci Eng. 2021 Nov 8;7(11):5288-5300 [PMID: 34661396]
  40. Med Sci (Basel). 2023 Jun 13;11(2): [PMID: 37367741]
  41. BMC Cancer. 2023 Jan 13;23(1):47 [PMID: 36639629]
  42. Med. 2023 May 12;4(5):290-310.e12 [PMID: 37178682]
  43. Head Neck. 2016 Apr;38 Suppl 1:E911-5 [PMID: 25994489]
  44. Clin Cancer Res. 2011 Dec 1;17(23):7248-64 [PMID: 21868764]
  45. Lancet Oncol. 2019 Jun;20(6):e313-e326 [PMID: 31162105]
  46. Int J Mol Sci. 2023 Feb 13;24(4): [PMID: 36835181]
  47. J Pharm Sci. 2011 Jan;100(1):59-74 [PMID: 20533556]
  48. Otolaryngol Head Neck Surg. 2014 Jan;150(1):73-80 [PMID: 24098006]
  49. Cancers (Basel). 2020 Aug 18;12(8): [PMID: 32824777]
  50. Adv Biosyst. 2017 Oct;1(10): [PMID: 30221187]
  51. Cancers (Basel). 2020 Jun 07;12(6): [PMID: 32517381]
  52. J Nanobiotechnology. 2023 Aug 2;21(1):249 [PMID: 37533100]
  53. Nat Biotechnol. 2014 Aug;32(8):773-85 [PMID: 25093879]
  54. Cancer Cell Int. 2019 Jan 14;19:16 [PMID: 30651721]
  55. Cancers (Basel). 2020 Dec 12;12(12): [PMID: 33322840]
  56. Int J Cancer. 2021 Apr 5;: [PMID: 33818764]
  57. Cell Stem Cell. 2020 Jan 2;26(1):17-26.e6 [PMID: 31761724]
  58. J Clin Med. 2019 Oct 15;8(10): [PMID: 31618880]
  59. Int J Cancer. 2019 Sep 1;145(5):1358-1370 [PMID: 30785217]
  60. Integr Biol (Camb). 2014 Jun;6(6):603-10 [PMID: 24763498]
  61. PLoS Biol. 2017 Jan 12;15(1):e2000719 [PMID: 28081116]
  62. CA Cancer J Clin. 2019 Jan;69(1):7-34 [PMID: 30620402]
  63. Cancers Head Neck. 2020 Jul 23;5:9 [PMID: 32714605]
  64. Nat Rev Dis Primers. 2020 Nov 26;6(1):92 [PMID: 33243986]
  65. Transl Oncol. 2019 Apr;12(4):633-639 [PMID: 30797141]
  66. Cancer Discov. 2019 Jul;9(7):852-871 [PMID: 31053628]
  67. J Biol Eng. 2023 Aug 17;17(1):53 [PMID: 37592292]
  68. Int J Mol Sci. 2015 Mar 11;16(3):5517-27 [PMID: 25768338]
  69. Biomaterials. 2010 Oct;31(28):7250-6 [PMID: 20580082]
  70. Nat Protoc. 2020 Oct;15(10):3380-3409 [PMID: 32929210]
  71. Mol Cancer Res. 2018 Nov;16(11):1798-1808 [PMID: 30042174]
  72. Front Med (Lausanne). 2022 Sep 07;9:971726 [PMID: 36160162]
  73. N Engl J Med. 2008 Sep 11;359(11):1116-27 [PMID: 18784101]
  74. PLoS One. 2016 Aug 08;11(8):e0160615 [PMID: 27501241]
  75. Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732): [PMID: 28893937]
  76. J Vis Exp. 2018 Apr 20;(134): [PMID: 29733308]
  77. Front Oncol. 2022 Aug 03;12:960340 [PMID: 35992863]
  78. Otolaryngol Head Neck Surg. 1997 Feb;116(2):213-22 [PMID: 9051067]
  79. Br J Cancer. 2023 May;128(10):1819-1827 [PMID: 36765175]
  80. Sci Rep. 2020 Feb 27;10(1):3652 [PMID: 32107458]
  81. Nat Methods. 2007 Oct;4(10):855-60 [PMID: 17767164]
  82. Nat Protoc. 2009;4(3):309-24 [PMID: 19214182]
  83. J Control Release. 2018 Jan 28;270:246-259 [PMID: 29233763]
  84. Mol Clin Oncol. 2017 Jul;7(1):151-157 [PMID: 28685095]
  85. Microorganisms. 2021 May 06;9(5): [PMID: 34066342]
  86. Int J Cancer. 2020 Dec 1;147(11):3236-3249 [PMID: 32478869]
  87. J Nanobiotechnology. 2021 Jan 6;19(1):3 [PMID: 33407564]
  88. Methods Mol Biol. 2023;2660:1-11 [PMID: 37191786]
  89. Mund Kiefer Gesichtschir. 1998 Sep;2(5):256-60 [PMID: 9816824]
  90. Am J Cancer Res. 2019 Apr 01;9(4):644-649 [PMID: 31105993]
  91. Diagnostics (Basel). 2023 May 19;13(10): [PMID: 37238282]
  92. BMC Cancer. 2023 Mar 9;23(1):223 [PMID: 36894916]
  93. ACS Biomater Sci Eng. 2020 Sep 14;6(9):4862-4869 [PMID: 33395269]
  94. Int J Radiat Biol. 2007 Nov-Dec;83(11-12):849-71 [PMID: 18058370]
  95. J R Soc Interface. 2017 Feb;14(127): [PMID: 28202590]
  96. Int J Mol Sci. 2021 Jul 31;22(15): [PMID: 34361027]
  97. Oncotarget. 2016 Mar 29;7(13):16948-61 [PMID: 26918944]
  98. Biotechnol Adv. 2016 Dec;34(8):1427-1441 [PMID: 27845258]
  99. Int J Oncol. 2017 Oct;51(4):1227-1238 [PMID: 28902347]
  100. SLAS Discov. 2021 Dec;26(10):1268-1279 [PMID: 34697958]
  101. Genome Integr. 2013 Oct 24;4(1):5 [PMID: 24152759]
  102. Cell Stem Cell. 2019 Jan 3;24(1):12-24 [PMID: 30581078]
  103. SLAS Discov. 2020 Apr;25(4):329-349 [PMID: 31983262]
  104. Expert Opin Drug Discov. 2015 Mar;10(3):257-68 [PMID: 25662589]
  105. J Cancer Res Clin Oncol. 2020 Oct;146(10):2497-2507 [PMID: 32620987]
  106. BMC Cancer. 2023 Aug 14;23(1):750 [PMID: 37580662]
  107. PLoS One. 2009 Jul 30;4(7):e6434 [PMID: 19649326]
  108. Crit Rev Oncol Hematol. 2022 Jul;175:103724 [PMID: 35609774]
  109. Br J Cancer. 2014 Jan 21;110(2):479-88 [PMID: 24263061]
  110. Cancer Res. 2006 Feb 15;66(4):1990-9 [PMID: 16488998]
  111. Nat Rev Cancer. 2018 Jul;18(7):407-418 [PMID: 29692415]
  112. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2206-11 [PMID: 26858399]
  113. Front Pharmacol. 2018 Nov 13;9:1300 [PMID: 30483135]
  114. Mol Cancer Res. 2014 Apr;12(4):571-82 [PMID: 24425785]
  115. Exp Cell Res. 2021 Aug 15;405(2):112725 [PMID: 34224701]
  116. Br J Cancer. 2011 Nov 8;105(10):1582-92 [PMID: 21989184]
  117. Front Cell Dev Biol. 2021 Jul 08;9:666515 [PMID: 34307351]
  118. Clin Transl Radiat Oncol. 2021 Feb 03;27:139-146 [PMID: 33665383]
  119. Cancers (Basel). 2020 Sep 23;12(10): [PMID: 32977530]
  120. Lancet Oncol. 2016 Jul;17(7):956-965 [PMID: 27247226]
  121. Exp Biol Med (Maywood). 2016 May;241(9):939-54 [PMID: 27072562]
  122. Front Oncol. 2019 Jan 22;9:17 [PMID: 30723707]
  123. Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11 [PMID: 30344100]
  124. Mol Carcinog. 2013 Mar;52(3):167-82 [PMID: 22162252]
  125. Biotechnol J. 2006 Sep;1(9):910-7 [PMID: 16941443]
  126. Anal Sci. 2023 Jun;39(6):771-778 [PMID: 36848001]
  127. BMC Cancer. 2019 Mar 25;19(1):265 [PMID: 30909875]
  128. J Biomol Screen. 2006 Dec;11(8):922-32 [PMID: 16973921]
  129. Oncotarget. 2018 May 18;9(38):25034-25047 [PMID: 29861851]
  130. Drug Discov Today. 2015 Jul;20(7):848-55 [PMID: 25908576]
  131. Trends Biotechnol. 2004 Apr;22(4):195-202 [PMID: 15038925]
  132. J Biomed Mater Res B Appl Biomater. 2011 Jul;98(1):160-70 [PMID: 21504055]
  133. Assay Drug Dev Technol. 2019 Apr;17(3):140-149 [PMID: 30958703]
  134. Cancer Cell Int. 2020 Dec 22;20(1):599 [PMID: 33353547]
  135. Cell Mol Gastroenterol Hepatol. 2018 Sep 14;7(1):73-91 [PMID: 30510992]
  136. Front Cell Dev Biol. 2021 Jul 13;9:674219 [PMID: 34327198]
  137. ACS Biomater Sci Eng. 2016 Oct 10;2(10):1710-1721 [PMID: 28251176]
  138. Front Oncol. 2021 Mar 18;11:641980 [PMID: 33816288]
  139. Sci Rep. 2019 Apr 19;9(1):6327 [PMID: 31004114]
  140. Adv Healthc Mater. 2023 Jun;12(14):e2202279 [PMID: 36718949]
  141. J Control Release. 2012 Dec 10;164(2):192-204 [PMID: 22613880]
  142. Br J Cancer. 1981 Jun;43(6):772-85 [PMID: 7195729]
  143. J Proteomics. 2022 Feb 20;253:104454 [PMID: 34922012]
  144. Cell Adh Migr. 2014;8(5):517-24 [PMID: 25482628]
  145. Mol Cancer Ther. 2018 Sep;17(9):2060-2071 [PMID: 29970484]
  146. Bioprinting. 2021 Jun;22: [PMID: 34368488]
  147. Cancer Lett. 2021 Apr 28;504:58-66 [PMID: 33582211]
  148. Assay Drug Dev Technol. 2018 Jan;16(1):27-50 [PMID: 29215913]
  149. Adv Healthc Mater. 2020 Apr;9(7):e1901773 [PMID: 32125787]
  150. SLAS Discov. 2020 Aug;25(7):744-754 [PMID: 32349587]
  151. SLAS Discov. 2019 Mar;24(3):242-263 [PMID: 30500310]
  152. Pharmacol Ther. 2016 Jul;163:94-108 [PMID: 27063403]
  153. Front Oncol. 2022 Jul 06;12:900903 [PMID: 35875133]
  154. Cancer. 2021 Aug 15;127(16):3029-3030 [PMID: 34086348]
  155. Science. 2019 Jun 07;364(6444):952-955 [PMID: 31171691]
  156. Cell. 2018 Dec 13;175(7):1972-1988.e16 [PMID: 30550791]
  157. Nat Commun. 2022 Apr 7;13(1):1899 [PMID: 35393416]
  158. Int J Mol Sci. 2021 Aug 18;22(16): [PMID: 34445585]
  159. Cancer Biol Med. 2021 Mar 27;: [PMID: 33772505]
  160. Gene. 2019 Feb 20;686:203-212 [PMID: 30481551]
  161. Biomed Mater. 2023 Jun 02;18(4): [PMID: 37220760]
  162. ACS Omega. 2023 Jan 18;8(4):3630-3649 [PMID: 36743071]
  163. Exp Cell Res. 2001 May 15;266(1):74-86 [PMID: 11339826]
  164. Cancer Res. 2013 Jan 1;73(1):297-306 [PMID: 23074283]
  165. Altern Lab Anim. 2022 Nov;50(6):414-422 [PMID: 36263982]
  166. Ann Biomed Eng. 2017 Jan;45(1):148-163 [PMID: 27126775]
  167. Ann Transl Med. 2022 May;10(9):526 [PMID: 35928731]
  168. Cancers (Basel). 2021 Jul 27;13(15): [PMID: 34359661]
  169. Biomaterials. 2018 May;164:54-69 [PMID: 29490260]
  170. Science. 2018 Feb 23;359(6378):920-926 [PMID: 29472484]
  171. Commun Biol. 2021 Dec 10;4(1):1387 [PMID: 34893703]
  172. Cancer Cell Int. 2021 Mar 4;21(1):152 [PMID: 33663530]
  173. Drug Des Devel Ther. 2014 Oct 14;8:1911-21 [PMID: 25342884]

Grants

  1. No. 075-15-2021-1356 (October 7, 2021; internal No. of the Agreement - 15.SIN.21.0011; identifier RF0951.61321X0012)/The Ministry of Education and Science of the Russian Federation
  2. No. 122030200537-5./State Assignment

Word Cloud

Created with Highcharts 10.0.0modelscellseveralHNSCCviraltumorvitroclinicalheadnecksquamouscarcinomacellularprimarycultures3Dtissuescientificengineeringstudyusinginfectiondecadesnowresearcherstryinganswerdemandoncologistscreateidealpreclinicalmodelaccessiblereproduciblerelevantpastyearsdevelopmenttechnologiesnaturallyallowedusmoveprimitiveshort-lived2Dcomplexpatient-derivedreproducecompositionarchitecturemutationalloadnativeDependingtaskscapabilitieslaboratorycanchoosetypesmodels:immortalizedlinesspheroidsheterospheroidsbioprintedorganoidsexplantshistoculturesmakepossiblescreenagentspotentialantitumoractivitycontributionmicroenvironmentprogressionmetastasisdetermineprognosticsignificanceindividualbiomarkersincludinggeneticmethodseffectpathogenesisdiseaseadjusttreatmenttacticsspecificpatientgroupspatientsPromisingexperimentalresultscreatedbasisregistrationstudiesVitroModelsHeadNeckCancer:PrimitiveAdvancedpersonalizedmedicine

Similar Articles

Cited By